A Systematic Analysis of Host Factors Reveals a Med23-Interferon-λ Regulatory Axis against Herpes Simplex Virus Type 1 Replication by Griffiths, Samantha J et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Systematic Analysis of Host Factors Reveals a Med23-
Interferon- Regulatory Axis against Herpes Simplex Virus Type 1
Replication
Citation for published version:
Griffiths, SJ, Koegl, M, Boutell, C, Zenner, HL, Crump, CM, Pica, F, Gonzalez, O, Friedel, CC, Barry, G,
Martin, K, Craigon, MH, Chen, R, Kaza, LN, Fossum, E, Fazakerley, JK, Efstathiou, S, Volpi, A, Zimmer, R,
Ghazal, P & Haas, J 2013, 'A Systematic Analysis of Host Factors Reveals a Med23-Interferon- Regulatory
Axis against Herpes Simplex Virus Type 1 Replication' PLoS Pathogens, vol. 9, no. 8, e1003514. DOI:
10.1371/journal.ppat.1003514
Digital Object Identifier (DOI):
10.1371/journal.ppat.1003514
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS Pathogens
Publisher Rights Statement:
Copyright: © 2013 Griffiths et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
A Systematic Analysis of Host Factors Reveals a Med23-
Interferon-l Regulatory Axis against Herpes Simplex
Virus Type 1 Replication
Samantha J. Griffiths1, Manfred Koegl2, Chris Boutell3, Helen L. Zenner4, Colin M. Crump4,
Francesca Pica5, Orland Gonzalez6, Caroline C. Friedel6, Gerald Barry7, Kim Martin1, Marie H. Craigon1,
Rui Chen1, Lakshmi N. Kaza1, Even Fossum1, John K. Fazakerley7, Stacey Efstathiou4, Antonio Volpi5,
Ralf Zimmer6, Peter Ghazal1,8, Ju¨rgen Haas1,9*
1Division of Pathway Medicine, University of Edinburgh, Edinburgh, United Kingdom, 2 Preclinical Target Development and Genomics and Proteomics Core Facilities,
German Cancer Research Center, Heidelberg, Germany, 3MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom, 4Division of Virology,
Department of Pathology Cambridge University, Cambridge, United Kingdom, 5University of Rome Tor Vergata, Rome, Italy, 6 Institute for Informatics, Ludwig-
Maximilians Universita¨t Mu¨nchen, Mu¨nchen, Germany, 7 The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United
Kingdom, 8Centre for Systems Biology at Edinburgh, University of Edinburgh, Edinburgh, United Kingdom, 9Max von Pettenkofer Institut, Ludwig-Maximilians Universita¨t
Mu¨nchen, Mu¨nchen, Germany
Abstract
Herpes simplex virus type 1 (HSV-1) is a neurotropic virus causing vesicular oral or genital skin lesions, meningitis and other
diseases particularly harmful in immunocompromised individuals. To comprehensively investigate the complex interaction
between HSV-1 and its host we combined two genome-scale screens for host factors (HFs) involved in virus replication. A
yeast two-hybrid screen for protein interactions and a RNA interference (RNAi) screen with a druggable genome small
interfering RNA (siRNA) library confirmed existing and identified novel HFs which functionally influence HSV-1 infection.
Bioinformatic analyses found the 358 HFs were enriched for several pathways and multi-protein complexes. Of particular
interest was the identification of Med23 as a strongly anti-viral component of the largely pro-viral Mediator complex, which
links specific transcription factors to RNA polymerase II. The anti-viral effect of Med23 on HSV-1 replication was confirmed in
gain-of-function gene overexpression experiments, and this inhibitory effect was specific to HSV-1, as a range of other
viruses including Vaccinia virus and Semliki Forest virus were unaffected by Med23 depletion. We found Med23 significantly
upregulated expression of the type III interferon family (IFN-l) at the mRNA and protein level by directly interacting with the
transcription factor IRF7. The synergistic effect of Med23 and IRF7 on IFN-l induction suggests this is the major transcription
factor for IFN-l expression. Genotypic analysis of patients suffering recurrent orofacial HSV-1 outbreaks, previously shown to
be deficient in IFN-l secretion, found a significant correlation with a single nucleotide polymorphism in the IFN-l3 (IL28b)
promoter strongly linked to Hepatitis C disease and treatment outcome. This paper describes a link between Med23 and
IFN-l, provides evidence for the crucial role of IFN-l in HSV-1 immune control, and highlights the power of integrative
genome-scale approaches to identify HFs critical for disease progression and outcome.
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Introduction
Up to 90% of the global population is infected with the a-
herpesvirus Herpes simplex virus type I (HSV-1). Whilst HSV-1 is
largely responsible for outbreaks of vesicular oral skin lesions (fever
blisters, or cold sores), it can also cause a variety of more severe
diseases including encephalitis, meningitis and keratitis [1,2].
Furthermore, the frequency of association with genital lesions
(previously associated mainly with HSV-2 infection) is increasing.
As co-infection with HSV is a significant contributing factor to
transmission of the Human Immunodeficiency Virus (HIV), our
understanding of HSV disease, and herpesviruses in general, has
wide implications for global healthcare.
Like all herpesviruses, HSV-1 establishes lytic (epithelial cells)
and asymptomatic latent infection (sensory neurons in trigeminal
and sacral ganglia) which undergoes periodic reactivation [3]. The
equilibrium between these two infection states requires a fine
balance between innate and adaptive immune responses, and viral
immune evasion mechanisms [4]. Whilst aspects of the HSV-1
replication cycle have been intensively investigated, there remain
gaps in our understanding of the complexity of virus:host
interactions. For example, a proteomics study identified over
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100 changes in the cellular proteome within the first 6h of
infection with HSV-1 [5], and a recent analysis of virion-
incorporated cellular proteins found that about 30% of these
directly affected virus growth [6].
To systematically identify host factors (HFs) required for viral
replication, RNAi screens have been performed with a range of
different RNA and DNA viruses including HIV-1 [7,8,9],
Influenza A virus [10,11,12], Hepatitis C virus [13], West Nile
virus [14], Dengue virus [15], Enterovirus [16] and Vaccinia virus
[17,18]. The overlap between the results of these studies is
generally very low [19], reflecting either differences in biology, or
different experimental set-ups, cutoff and selection criteria. In
addition, microenvironmental effects might also play a role for the
differences of the results [20].
Whilst loss-of-function siRNA screens provide functional
information on specific genes, protein interaction studies can
provide insight into the mechanism of action by identifying
physical interaction partners between pathogen and host.
Genome-scale virus-host protein interaction screens using the
yeast-two-hybrid system have been performed for HCV [21],
Influenza A virus [22], Epstein Barr virus (EBV) [23], Vaccinia
virus [24,25], SARS coronavirus [26] and several non-human
viruses [27]. Based on these genome-scale studies and individual
interactions found by literature curation, several virus-host
interaction databases have been created including the HIV-1,
human protein interaction database at NCBI [28], VirHostNet
[29], VirusMINT [30], PIG [31] and HPIDB [32]. Although there
is little overlap between individual cellular interactors of different
viruses, targeting of a number of cellular processes such as cell
cycle regulation, nuclear transport and immune response appears
to be conserved [33].
Understanding the complex interplay between viral and host
components is critical to the definition of herpesvirus infection and
pathogenesis. As herpesviruses encode a large number of proteins,
in contrast to small RNA viruses such as HIV and Influenza, many
cellular processes may be directly affected by viral proteins, and
whilst there exists a wealth of information on individual viral
proteins, there remain large gaps in our understanding of the
HSV-1 life cycle and its interaction with its host. Here, we present
data from the first integrative and systematic screening approach
to characterise the role of cellular proteins in the HSV-1 life cycle.
A genome-scale RNAi knockdown screen to identify HFs
functionally influencing HSV-1 replication was performed in
parallel with a yeast two-hybrid (Y2H) protein interaction screen
to simultaneously gain insight into potential mechanisms of action.
Combined analyses confirmed the importance of known cellular
proteins involved in processes such as cell cycle, proteins transport
and gene expression important for virus replication. Furthermore,
we identified a subunit of the Mediator multi-protein complex,
Med23, as a key regulator of IFN-l induction, which appears to be
of crucial significance for the control of HSV-1 both in vitro and in
vivo. These data demonstrate the power of a combined screening
strategy to investigate pathogen:host interactions and identify
novel host factors and cellular pathway targets for the develop-
ment of essential clinical interventions.
Results
A siRNA depletion screen identifies host factors (HFs) for
HSV-1 replication
Host factors (HFs) which positively or negatively regulate HSV-1
replication were identified by screening a druggable genome siRNA
library (4 siRNAs per gene) targeting 7,237 human genes against a
HSV-1 reporter virus expressing the enhanced green fluorescent
protein (eGFP; HSV-1 strain C12) in the epithelial Hela cell line, due
to their ease of transfection and susceptibility to HSV-1 infection [34].
To generate a robust and reliable dataset the screen was carried out
three times in triplicate, with one replicate used in a cell viability assay
to determine any cytotoxic effects of gene depletion and duplicates
infected for the virus infection assay. The siRNA library was reverse-
transfected into Hela cells before infecting with HSV-1 and
monitoring virus growth kinetics as a measure of GFP-fluorescence
(Figure 1b). By following virus growth over multiple rounds of
replication, host proteins involved in all stages of the virus life cycle
can be identified. Replication slopes during linear growth were
normalized to controls (mock-transfected cells, and cells transfected
with a siRNA unable to be processed by the RNA Silencing
Complex, RSCF) and the mean of six replicates was calculated.
siRNAs found to be cytotoxic (81 in total) were excluded from further
analyses, and a hitlist of 358 containing the top 2.5% inhibitory and
the top 2.5% enhancing HFs was generated (Table S1 in Text S2).
The identifiedHSV-1HFs were compared to datasets from published
siRNA depletion screens aimed at identifying cellular factors affecting
HIV-1 [7,8,9], West Nile Virus (WNV) [14], Hepatitis C Virus
(HCV) [13], Dengue virus [15] and Influenza A virus [10,11,12]. Of
our 358 HFs, 54 cellular proteins (15.1%) overlapped with these other
virus screens (Influenza A, 29; HIV-1, 24; HCV, 6; WNV, 2; Dengue
virus, 1) (Figure 1c; Table S2 in Text S2).
A genome-scale yeast two-hybrid protein interaction
screen identifies novel viral protein interaction partners
HSV-1 is currently known to encode at least 84 proteins,
expressed sequentially under strict temporal regulation during
Author Summary
Herpes simplex virus type 1 (HSV-1) infects the vast
majority of the global population. Whilst most people
experience the relatively mild symptoms of cold sores,
some individuals suffer more serious diseases like viral
meningitis and encephalitis. HSV-1 is also becoming more
common as a cause of genital herpes, traditionally
associated with HSV-2 infection. Co-infection with HSV-2
is a major contributor to HIV transmission, so a better
understanding of HSV-1/HSV-2 disease has wide implica-
tions for global healthcare. After initial infection, all
herpesviruses have the ability to remain dormant, and
can awaken to cause a symptomatic infection at any stage.
Whether the virus remains dormant or active is the result
of a finely tuned balance between our immune system and
evasion techniques developed by the virus. In this study
we have found a new method by which the replication of
the virus is counteracted. The cellular protein Med23 was
found to actively induce an innate anti-viral immune
response in the form of the Type III interferons (IFN-
lambda), by binding IRF7, a key regulator of interferons,
and modulating its activity. Interferon lambda is well
known to be important in the control of Hepatitis C
infection, and a genetic mutation correlating to an
increase in interferon lambda levels is strongly linked to
clearance of infection. Here we find the same association
between this genetic mutation and the clinical severity of
recurrent cases of HSV-1 infection (coldsores). These data
identify a Med23-interferon lambda regulatory axis of
innate immunity, show that interferon lambda plays a
significant role in HSV-1 infection, and contribute to the
expanding evidence for interferon lambda in disease
control.
Med23-IFN-l Regulation of HSV-1 Replication
PLOS Pathogens | www.plospathogens.org 2 August 2013 | Volume 9 | Issue 8 | e1003514
infection. To gain further mechanistic insight into host factors
involved in HSV-1 infection, in parallel to the siRNA depletion
screen we carried out a yeast two-hybrid protein interaction screen
to identify cellular interaction partners of viral proteins. We
generated a collection of 107 partial and full-length HSV-1 cDNA
constructs and tested them for interactions with proteins encoded
by a library of 12,381 human cDNA clones [35]. 231 HSV-1-
human protein interactions were detected once (low confidence),
and 63 more than once (high-confidence)(Table S3 in Text S2).
Using these high-confidence interactions, the previously reported
HSV-1 interactome [36] was connected into a human interactome
(62,310 published protein interactions) to generate a combined
pathogen-host interactome (Figure S1a). Both degree centrality
(which indicates the number of interactions a protein has, where
high values represent highly interactive ‘hubs’) and betweenness
centrality (which indicates the number of shortest paths between
Figure 1. Identification of HSV-1 host factors by RNAi and Y2H screens. (a) Strategy to identify host factors interacting with viral proteins or
influencing HSV-1 replication. (b) RNAi perturbation screen by kinetic analysis of HSV-1 replication. Hela cells were reverse-transfected with siRNA
SMARTpools (4 siRNAs per gene). After 48 h the siRNAs were tested for cytotoxicity (3 replicates) or the capacity to influence replication of the HSV-1
GFP reporter virus C12 (6 replicates) from 24 to 80 h post-infection. Virus replication slopes during the linear phase were calculated and normalized to
mock-transfected cells. Replication slopes were then compared to replication upon knockdown of essential (ICP4, VP16) or non-essential (VP11/12)
viral genes, a cellular receptor for HSV-1 (HVEM) or control RISC-free siRNA (RSCF). (c) Overlap between the HSV-1 HFs identified in this study with
those published in HIV-1 [7,8,9], Hepatitis C Virus (HCV) [13] and Influenza A virus [10,11,12].
doi:10.1371/journal.ppat.1003514.g001
Med23-IFN-l Regulation of HSV-1 Replication
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any pair of proteins passing through the protein considered) were
significantly increased for HSV-1 interactors, particularly in the
high-confidence network (Figure S1b–e). These data suggest
HSV-1 proteins preferentially target highly connected central
human proteins in the cellular interaction network, similar to other
viruses [23].
Analysis of this interactome for HFs identified by RNAi found
they were enriched in the fraction of cellular proteins that directly
interact with viral proteins or that interact via one intermediate, in
comparison to proteins that only interact via 2 or more
intermediates (p=0.036, Fisher’s exact test)(Figure S1f). A direct
comparison of HSV-1 protein interaction partners and the siRNA
screen HFs found 215 genes in common. Of those, ten (4.6%) were
identified as a hit in both screens (Table S4 in Text S2),
suggesting that these technologies identify complimentary yet not
necessarily overlapping HFs.
Validity and specificity of HSV-1 HFs
An extended literature and database search identified 599
cellular proteins that interact with or are involved in infection with
human herpesviruses. The overlap between the high-confidence
Y2H cellular interactors (63) and HFs (358) with this set was
statistically significant (p = 0.008) (Figure 2a; Figure S1h;
Table S5 in Text S2). From this combined analysis, a subset
of HFs was chosen for further validation. Protein interactions were
tested in a mammalian cell system by LUMIER pull-down assay
[37]. Of the 45 interactions tested, 26 (57.8%) were confirmed,
with 15 strongly positive (z-score .2) and 11 weakly positive (z-
score 1–2) (Figure S1g). siRNA deconvolution (4 siRNAs per
gene tested individually) was used to further validate 72 HFs
(Figure 2b; Figure S2). The replication phenotype could be
confirmed ($2 or more siRNAs gave the same or better
replication slope than observed in the primary screen) in a high
proportion (83.3%) of candidates, highlighting the reliability of the
primary screen dataset. Quantitative RT-PCR analysis of mRNA
expression levels found a minimum depletion of 60% (mean 88%)
in a subset of 52 genes (data not shown; Table S6 in Text S2)
confirming the observed effects on HSV-1 replication are genuine
and not due to ‘off-target’ effects or insufficient gene knockdown.
To further investigate the virus-specificity of our identified HFs,
we tested this subset for their effect on the replication of an
additional a-herpesvirus (Varicella-Zoster virus, VZV), the b-
herpesvirus Cytomegalovirus (CMV), and a completely unrelated
RNA virus, Semliki Forest Virus (SFV). None of the three proteins
which enhanced HSV-1 replication upon knockdown had an effect
on either VZV or CMV, and one (NR3C2) was even inhibitory for
SFV (Figure 2c). Of the 64 siRNAs which inhibited HSV-1, 27
(42.2%) were also inhibitory for VZV, 60 for CMV (93.8%) and
23 (35.9%) for SFV replication (Table S7 in Text S2). Some
functional groups (transcriptional regulators) were required by
most viruses, but there were notable differences between other
proteins. For example IFITM-1, previously identified as an
inhibitor of Influenza A, Dengue virus and WNV [10], inhibited
VZV yet had a positive effect on HSV-1 replication. These data
suggest that whilst there are some HFs which are broad in their
effects on virus replication, a large proportion are species-specific.
HSV-1 HFs are involved in diverse cellular pathways and
at multiple stages of the HSV-1 life cycle
Functional and pathway analysis of the 358 HSV-1 HFs
identified in the siRNA depletion screen (Figure S3a), and of
direct and indirect virus-host interactions with multiple interaction
partners (Figure S3b), found a significant enrichment of a wide
range of cellular processes involved in multiple stages of virus
replication (Table S8 in Text S2). Pathways included those
involved in gene expression, transcription, splicing and transla-
tional regulation (RNAi screen), and protein transport, cell cycle,
and transcriptional repressor activity (Y2H screen). A combined
analysis of HFs from both screens found dominant functional
categories centred on the regulation of transcription (RNA
polymerase II-associated genes, splicing factors, transcription
activation and the Mediator complex) (Figure S3c, d). The
physiological relevance of some HFs and pathways was confirmed
by further biological validation. Protein transport pathways (in the
form of dynein microtubule networks) are exploited by HSV-1
early after infection to shuttle viral capsids to the nucleus. These
screens confirmed known interactions between dynein subunits
and viral proteins, and identified additional previously unknown
interactions (Text S1 and Figure S4a). Several dynein chain
subunits were found to be essential for virus replication, whilst the
moderate effect of depletion of other subunits demonstrated a level
of functional redundancy in HSV-1 capsid transport (Figure
S4b–e) [38,39]. Intrinsic anti-viral host defense mechanisms, in
the context of cellular E2 ubiquitin ligases, were also investigated.
The immediate-early viral protein ICP0, an E3 ubiquitin ligase, is
crucial for blocking anti-viral defense mechanisms by degrading
promyeloctic leukemia (PML) nuclear bodies (ND10 domains) in
the presence of cellular E2-ubiquitin-conjugating enzymes (E2s).
Our siRNA screen found multiple E2s were required for this, and
suggests that HSV-1 ICP0 is promiscuous in its exploitation of E2s
to mediate PML degradation and ensure successful infection (Text
S1 and Figure S5).
Med23 is an anti-viral component of the pro-viral
Mediator complex
Combined bioinformatic analyses of protein interaction and
siRNA depletion screens found a significant functional enrichment
for proteins involved in transcription, and identified multi-protein
complexes enriched for pro-viral HFs which strongly inhibited
HSV-1 upon depletion, including the RNA-polymerase II, eIF3
and Mediator complexes (Figure 3a). The Mediator complex
links the cellular transcription machinery (RNA polymerase II) to
specific transcription factors, and the identification of many
Mediator subunits as HFs in other viral siRNA depletion screens
highlights its significant role in viral genome transcription
[7,9,11,40] (Table S2 in Text S2). Further, several Mediator
subunits (Med25, 29, 17 and 8) are known to interact with the
HSV-1 transactivator VP16 (UL48) and other herpesviral proteins
[41] (Figure S6a). Consistently, the Mediator complex was found
to be strongly required for HSV-1 replication, with depletion of
the majority of subunits (Med 4, 6, 7, 8, 14, 16, 17, 21, 25, 26, 27
and 28) leading to a severe reduction in virus replication in the
primary screen (Figure S6b) or in confirmatory deconvolution
assays (Figure 3b). However, depletion of the Med23 subunit was
striking in that it led to a significant enhancement of virus growth
(Figure 3b). Flow cytometry quantification found that removal of
Med23 not only increased the total number of infected cells
(combination of GFPlo and GFPhi cells; 75.5% in comparison to
49.6% in mock-transfected cells) but also the copy number of virus
genomes (GFPhi cells; 44.8% in comparison to 24.4% in mock-
transfected cells) (Figure 3c). Gain-of-function experiments found
overexpression of Med23 led to a corresponding inhibition of two
strains of HSV-1 (Figure 3d; Figure S6c), confirming Med23 is
a natural anti-viral component of the pro-viral Mediator complex.
This anti-viral effect of Med23 was specific for HSV-1, as
replication of VZV (a-herpesvirus), hCMV (b-herpesvirus),
Vaccinia virus (DNA) and SFV (RNA virus) remained unaffected
by Med23 depletion (Figure 3e).
Med23-IFN-l Regulation of HSV-1 Replication
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Figure 2. Primary validation of HFs for HSV-1. (a) Overlap between HSV-1 HFs, cellular protein interactors of HSV-1 proteins identified by Y2H
system, and published protein interactors of all human herpesviral proteins. (b) Validation of a subset of HFs by siRNA deconvolution. A subset of HFs
Med23-IFN-l Regulation of HSV-1 Replication
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Med23 inhibits HSV-1 replication by inducing a type III
interferon (IFN-l) response
Med23 could exert anti-viral effects either by having an
inhibitory effect on viral transactivators or by interacting with
and having a positive effect on an existing anti-viral factor. We first
tested whether Med23 directly affects viral gene expression using
luciferase reporters with HSV-1 promoters, however observed no
inhibitory effect (data not shown). Since the Mediator complex
and Med23 in particular is known to be involved in Jak/Stat-
mediated interferon signaling [42], we used the lung epithelial cell
line A549 and its Stat-1-deficient derivative A549-V [43] to
determine if Med23 influences HSV-1 replication by modulating
innate immunity. In the parental A549 cells the phenotype of
HSV-1 replication was the same as that observed in Hela cells,
where depletion of Med23 enhanced replication and over-
expression inhibited virus growth. However, in the Stat1-deficient
A549-V cells HSV-1 replication was unaffected by both depletion
and over-expression of Med23 (Fig. 4a), indicating that Med23
requires an intact Jak/Stat signalling pathway to exert its anti-viral
effects.
To determine which interferon may be responsible for the anti-
viral effects of Med23, A549 cells were depleted for Med23 and
infected with HSV-1 following pre-stimulation with Type I (IFN-a
or IFN-b), Type II (IFN-c) or Type III (the distinct IFN-l1 or the
almost identical IFN-l2 and -l3, termed IFN-l2/3) interferons.
Whilst treatment with IFN-a, -b and -c significantly decreased
HSV-1 replication levels, the observed ,2-fold enhancement of
HSV-1 replication following Med23 depletion was still seen.
However, pre-treatment with the both IFN-l1 and IFN-l2/3
blocked the enhancing effect of Med23 depletion (Figure 4b).
Investigation into the effect of Med23 on interferon induction by
qRT-PCR found that whilst Med23 over-expression induced IFN-
b (,3-fold increase), induction of IFN-l1 and l2/3 was
considerably and statistically significantly higher (,26-fold induc-
tion; p=0.003 and 0.002, respectively) (Figure 4c). This
induction was specific, as levels of other cytokines and interfer-
on-regulatory factors (IRFs) were unaffected by Med23 overex-
pression (Figure S7a). Secretion of IFN-l2/3 protein was also
increased in all cell lines tested, but most significantly to ,11-fold
in A549 cells (Figure 4d), which is consistent with a recent report
showing that type III interferons are the dominant type of IFNs
expressed by primary airway epithelial cells [44]. Furthermore,
qPCR analysis found depletion of Med23 inhibited the induction
of IFN-l expression following HSV-1 infection of A549 cells in
comparison to cells transfected with the RSCF siRNA control
(Figure 4e). Together, these data suggest that IFN-l is
responsible for the observed inhibitory effect of Med23 on HSV-
1 replication.
IFN-l is synergistically induced following a direct
interaction between Med23 and IRF7
As IFN-l expression is induced following activation of pathogen
recognition receptors (PRRs) by virus infection [45,46,47,48], we
tested whether Med23 induced IFN-l by directly interacting with
an interferon-responsive transcription factor (IRF). Y2H and
confirmatory co-immunoprecipitation experiments in mammalian
cells with a panel of IRFs found that Med23 interacted with IRF4
and IRF7 (Figure 5a; Figure S7b). We also observed a weak
interaction with IRF9, which may explain the previously observed
effect of Med23 on Jak/Stat signalling [42]. To determine if this
interaction had a functional effect, we looked at whether Med23
influenced IRF-mediated induction of IFN-l. In a luciferase
reporter assay, neither IRF4 nor IRF9 led to a significant
induction of the IFN-l1 promoter, either alone or in conjunction
with Med23 (data not shown). IRF7 induced expression from the
IFN-b and IFN-l1 promoters to similar levels (,7-fold and 9-fold
higher than background, respectively), whilst the ISRE, induced
by IRF7 and also present in the IRF7 promoter, was induced
,15-fold (Figure 5b). Whilst co-expression of Med23 with IRF7
had no further effect on IFN-b expression, a synergistic induction
of the IFN-l1 promoter and, to a lesser extent, the ISRE, was
observed (IFN-l1 doubled to ,18-fold, p = 0.02) (Figure 5b).
Interestingly, a Med23 mutant unable to induce immediate early
gene expression via jun/fos (R617Q, or R611Q in Med23
transcript variant 1 used here) synergistically induced ISRE
expression with IRF7, yet was unable to further enhance IRF7-
mediated induction of IFN-l1 (data not shown). A similar
synergistic effect of Med23 and IRF7 was seen at the protein
level, where co-expression increased supernatant levels of IFN-l3
more than 2-fold those seen with Med23 or IRF7 alone (Figure
S7c, d).
IFN-l gene expression is associated with the recurrence
and severity of recurrent HSV-1 disease
Successful disease and treatment outcome in Hepatitis C virus
infection (demonstration of a sustained virologic response) is
strongly associated with a single nucleotide polymorphism (SNP) in
the IFN-l3 promoter (rs12979860; CC genotype over CT or TT)
and higher plasma levels of IFN-l3 [49],[50]. Furthermore, IFN-l
expression is impaired in a cohort of ethnically Italian individuals
suffering recurrent HSV-1-related herpes labialis reactivation [51].
To determine if the clinical severity of HSV-1 disease is due to the
observed deficiency in IFN-l expression, we screened a subset of
the recurrent herpes labialis (HL) cohort and additional subjects
for the IFN-l3 promoter polymorphism. Genotypic analysis found
the presence of a T (CT or TT genotype) had a dose-dependent
association with clinical severity, with the homozygous TT
genotype being more prevalent as disease severity increases
(Figure 6). In spite of the relatively small sample numbers in
some clinical categories (Table 1), the association of a CT or TT
genotype with the most severe recurrence of herpes labialis (H+)
was statistically significant (p=0.014; Fishers’s exact t-test). As the
CC genotype is directly associated with increased IFN-l3 levels
[51], these data highlight a previously unknown association
between the frequency/severity of recurrence of herpes labialis,
the CT/TT genotype and subsequent reduction in secretion of
IFN-l3. It is of importance to investigate this genotype association
with a larger cohort of HL patients, as well as those suffering with
other HSV-1-related disease, in order to determine the role of
IFN-l in the full spectrum of HSV-1 pathogenesis.
was selected for validation with deconvoluted siRNAs to confirm the phenotype observed in the primary screen. The effect of the four individual
siRNAs (1–4) and a reconstituted SMARTpool (SP) were tested by reverse-transfecting into Hela cells before infecting after 48 h with HSV-1-eGFP (C12)
and monitoring replication. Replication slopes were calculated and normalized as described, and compared to the primary screen slope (1u). A heat
map of replication slopes was generated where red represents inhibition (replication slope ,0.5) and green represents enhancement (slope.1). The
phenotype was considered validated if $2 siRNAs produced the same or better phenotype as the primary screen. (c) Virus specificity of HSV-1 HFs.
The effect of HF siRNA SMARTpools on the replication of VZV (a-herpesvirus), hCMV (b-herpesvirus) or Semliki Forest virus (SFV; RNA virus) was
determined and compared to HSV-1. Normalized replication 626STDEV of the controls was considered inhibiting/enhancing.
doi:10.1371/journal.ppat.1003514.g002
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Figure 3. Med23 is a novel anti-viral HF against HSV-1. (a) Multiprotein complexes involved in HSV-1 replication. The distribution of replication
slopes of components from eight human protein complexes found to be critical to HSV-1 infection were ranked inhibiting (Rank 1, left) to enhancing
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Taken together, these data identify Med23 as a novel anti-viral
factor which acts as a key regulator of IFN-l expression by
interacting with and enhancing the activity of IRF7, a major
transcription factor involved in innate immunity. Our observation
of a link between the clinical severity of HSV-1 disease and, a CT/
TT genotype at a SNP known to regulate IFN-l3 secretion
demonstrates the significance of IFN-l in the control of HSV-1
replication in vivo. Whilst this study provides no direct link between
the IFN-l3 promoter polymorphism and Med23, these associa-
tions of IFN-l with HSV-1 disease, combined with our
observations that Med23 is required for the induction of IFN-l
following HSV-1 infection, identifies for the first time a link
between Med23 and IFN-l, provides a clinical context for Med23
regulation of IFN-l expression and underscores the potential
biological significance of these data.
The use of HSV-1 in a combined genome-scale screening
approach has led to the identification of a regulatory axis in anti-
viral innate immunity, and this important finding not only
highlights the power of such combined genome-scale screening
approaches to identify novel host candidates for anti-herpesvirus
drug discovery, but provides an invaluable dataset to the
herpesvirus and scientific community at large.
Discussion
By nature of their scale, high-throughput screening technologies
have limitations. RNAi technology is limited by technical issues
such as off-target effects, where an alternative gene to the intended
target is degraded, and insufficient gene knockdown. Similarly,
Y2H protein interaction screens can generate both false-positive
interactions, due to ‘sticky’ proteins and auto-activation of the
reporter gene used, and false-negative interactions. Whereas the
number of false positives can be considerably reduced by stringent
screening and selection criteria, the low sensitivity of the Y2H
assay, which detects 20–30% of known interactions, is inherent to
the system and can only be marginally improved. This poor
sensitivity is caused by factors such as structural restraints of the
Y2H bait and prey fusion proteins, a lack of or existence of distinct
protein modification in yeast cells, and cellular localization signals
in bait and prey proteins preventing nuclear import [52].
However, as all other high-throughput methods for measuring
binary protein interactions possess a similarly low sensitivity, but
are considerably more laborious and expensive, the Y2H system is
still the most commonly used technology [53].
In this study we have exploited a combined genome-wide
screening approach to investigate HSV-1 replication and interac-
tion with its host. This identified 358 functional HFs modulating
HSV-1 replication, and 63 cellular interaction partners. In
validation experiments, 57.8% of the interactions were confirmed
by co-immunoprecipitation assays in mammalian cells, and of the
358 functional HFs identified in the siRNA screen, the phenotype
of 83.3% was confirmed in deconvoluted siRNA experiments.
This, combined with qPCR data demonstrating a minimum gene
depletion of 69%, suggests that the functional phenotypes on virus
replication are genuine, and not due to ‘off-target’ effects. The
confirmation of such a high proportion of selected validation
candidates, in spite of the potential technical drawbacks, highlights
the reliability of our primary screen datasets, and thus provides an
invaluable resource for the herpesvirology research community.
One interesting outcome of this study was the surprisingly low
overlap between hits identified using these different technologies.
Of the 215 genes in common between the siRNA and cDNA
libraries, only 10 (4.7%) were classified as a hit by both methods.
This, however, is not unexpected, as even the overlap between
studies using the same technology has been reported to be low. For
example, the overlap between the three previously published HIV
screens was only 7% [19]. Furthermore, the degree of functional
redundancy within the siRNA library, and cellular pathways in
general, the potential situation-specificity of virus-host interactions,
and the possibility of indirect interactions between viral and host
proteins, suggest that these methodologies detecting functional
outcomes or physical interactions are linked, but complementary
rather than confirmatory.
The identified HFs were enriched for a range of cellular
processes, such as transcription, gene expression, protein transport
and cell cycle (Figure S2 and S3), and involved at different stages
of viral infection. We investigated HFs involved in capsid transport
and ubiquitination of antiviral intrinsic host defence factors in
more detail. Incoming HSV-1 capsids are transported to nuclear
pores via the microtubule-organizing centre (MTOC), mediated
by capsid proteins VP26 (UL35) and UL46 binding to the dynein
light chains DYNLT1 (Tctex1) and DYNLT3 (rp3) [54,55]. Our
Y2H screen confirmed the known interaction between the capsid
protein VP26 and the dynein light chain DYNLT3 (Text S1 and
Figure S4). Combined with the siRNA screen data, which found
depletion of multiple light chain subunits had moderate anti-viral
effects on HSV-1, these data confirm propositions of redundancy
in the capsid transport process which ensures successful infection
in the event of viral mutations [38,39], and provide further
evidence that HSV-1 has evolved to be highly promiscuous in its
exploitation of cellular pathways to its advantage.
To overcome the intrinsic host defence, HSV-1 induces a
proteasome-dependent degradation of anti-viral promyelocytic
leukemia (PML) nuclear bodies (ND10 domains) by the RING-
finger ubiquitin ligase ICP0 expressed during early infection [56].
In vitro, ICP0 is a biochemically active E3 ubiquitin ligase in the
presence of E2 ubiquitin conjugating enzymes (E2s) [UBE2D1
(UbcH5a) and UBE2E1 (UbcH6)] [57], but which E2s are used
during infection has remained unclear. We identified 20 cellular
E2s that are able to influence HSV-1 replication (Text S1 and
Figure S5). Depletion of UBE2D1-4, UBE2E1-3 and UBE2N
(Rank 7157, right). Arrow denotes Med23. (b) Deconvoluted siRNAs confirm role of Mediator subunits in HSV-1 replication. The effect of four
individual siRNAs (1–4) and a reconstituted SMARTpool (SP) on a range of subunits of the Mediator complex were compared to the primary screen (P).
Med25 was not present in the primary screen so has no comparative ‘P’. Hela cells were transfected and infected with HSV-1-eGFP. Replication slopes
were calculated and normalized to controls. Error bars represent the mean of three independent experiments done in duplicate. (c) Fluorescence
microscopy and FACS analysis of Hela cells depleted of Med23. Hela cells transfected with either ICP4 or Med23 siRNA SMARTpools were infected
with the recombinant HSV-1 GFP reporter virus C12 (MOI 1) and analysed by fluorescence microscopy and FACS analysis. Numbers indicate the
percentage of cells in the uninfected, GFPlo or GFPhi populations. (d) Overexpression of Med23 inhibits HSV-1 C12-GFP and VP26-YFP. Hela or HEK
cells overexpressing Med23 transiently (Hela) or stably (HEK) were infected with HSV-1 C12-eGFP or HSV-1 VP26-YFP at MOI 0.5. Replication slopes
were monitored and normalized to control (pCR3)-transfected cells. Error bars represent the mean of at least three independent experiments. (e)
Depletion of Med23 specifically affects HSV-1. Hela cells were depleted for Med23 with a siRNA SMARTPool and infected with HSV-1, Varicella zoster
virus (VZV), human cytomegalovirus (hCMV), Vaccinia virus (VacV) or Semliki Forest Virus (SFV). Replication slopes (HSV-1, VZV, hCMV, VacV) or
endpoint replication values (SFV) were calculated and normalized to controls. Error bars represent the mean of at least three independent
experiments.
doi:10.1371/journal.ppat.1003514.g003
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Figure 4. Med23 inhibits HSV-1 by inducing a Type III interferon (IFN-l) response. (a) Med23 depletion or over-expression has no effect in
A549-V cells deficient in Jak/Stat signalling. A549 cells and derivative A549-V cells were transfected with Med23 siRNA SMARTpool (Med23 KD) or a
pCR3-Med23 overexpression plasmid (Med23+) 48 h (siRNA) or 24 h (pCR3) before infection with HSV-1-eGFP C12. Replication was monitored, and
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slopes calculated and normalized to controls (RSCF siRNA or pCR3). Error bars represent the mean of at least three independent experiments. (b) Pre-
treatment with Type III interferons prevents Med23-mediated enhancement of HSV-1 replication. A549 cells were mock-transfected or transfected
with Med23 siRNA. After 48 h cells were untreated or pre-treated with 50 ng/ml IFN-a, IFN-b, IFN-c or 100 ng/ml IFN-l1 or IFN-l2/3 for 6 h, before
infecting with HSV-1-eGFP C12. Replication was monitored and slopes calculated and normalized to unstimulated, mock-transfected cells. (c)
Overexpression of Med23 preferentially induces type III interferons. pCR3 or Med23 were overexpressed in A549 cells and induction of type I (IFN-b)
and type III (IFN-l1, IFN-l2/3) was measured by qRT-PCR. mRNA levels were normalized to HPRT and calibrated to mock transfected cells (control).
Error bars represent the mean of technical replicates and is representative of multiple experiments. * = p-value 0.003; ** = p-value 0.002 (unpaired t-
tests for unequal variances). (d) Overexpression of Med23 induces IFN-l secretion. A range of cell types were transfected with pCR3 or Med23,
supernatant harvested 120 h post-transfection and IFN-l3 levels measured by ELISA. Chart shows the mean and standard deviation of duplicates
over two experiments. (e) siRNA depletion of Med23 inhibits the induction of IFN-l2/3 following HSV-1 infection. A549 cells were transfected with
control (RSCF) or Med23-specific siRNA (Med23 KD) before infecting with HSV-1-eGFP C12 (MOI 0.5). RNA was harvested 0 or 8 h post-infection and
IFN-l2/3 mRNA levels measured by qRT-PCR. Expression was normalized as above, and calibrated to RSCF-transfected cells at 0 h post-infection. Error
bars represent the mean of technical replicates and is representative of multiple experiments.
doi:10.1371/journal.ppat.1003514.g004
Figure 5. Med23 induces IFN-l by interacting with the transcription factor IRF7. (a) Med23 directly interacts with IRFs. Med23 was
overexpressed in HEK cells as a myc-tagged fusion protein individually with a range of HA-tagged IRFs. Protein amounts were quantified and equal
amounts (325 mg) were immunoprecipitated (IP) with anti-HA or anti-myc antibody before western blot analysis and staining with anti-HA (WB) to
confirm protein expression (IP; anti-HA IP) and identify interaction partners (Co-IP; anti-myc IP) (b) Med23 synergistically induces IRF7-responsive
promoters. A549 cells were transfected with IFN-l1-, IFN-b- or ISRE-responsive luciferase reporter constructs with IRF7 alone or in addition to Med23.
Promoter activity was determined by measurement of Firefly luciferase activity 33 hr post-transfection, and normalized to Renilla luciferase and pCR3-
transfected cells. Error bars represent the mean of at least three independent experiments. Statistical significance of the synergistic increase in IFN-l
induction by Med23 with IRF7 over IFN-b induction was determined by unpaired t-tests for unequal variances. * = p-value 0.02.
doi:10.1371/journal.ppat.1003514.g005
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significantly increased the number of PML-positive cells post-
infection, in an ICP0-dependent manner, indicating that ICP0 can
use multiple E2s to degrade PML [57,58].
One of the multi-protein complexes affecting HSV-1 replication
was the Mediator complex, a large (.30 subunits) complex which
links specific transcription factors to the RNA polymerase II
transcription machinery [40]. As the requirement of Mediator
subunits in the replication of herpes and other viruses is already
well-known [7,9,11,41], it was striking that depletion of the Med23
subunit exerted the opposite phenotype and led to a strong
increase in virus growth. The Mediator is composed of four
distinct modules termed the head, middle, tail and kinase domains,
which provide the Mediator with some degree of active control
over transcription [59]. As individual subunits of this large
complex interact with and exert functional effects via specific
transcription factors, it is not unexpected that the observed anti-
viral effects were specific to Med23 [60]. Within the Mediator,
Med23 forms a tight sub-complex with Med24 and Med16
[60,61]. The increase in virus replication observed upon depletion
of Med24 may be caused by the destabilisation of the structure of
this sub-complex (Figure S6b).
Investigations into the mechanism of action revealed Med23
inhibits HSV-1 replication by preferentially inducing a type III
interferon response (IFN-l) at the mRNA and protein level. This
induction was mediated via a direct interaction with the
transcription factor IRF7, which resulted in a synergistic increase
in IFN-l expression. Med23 was unable, however, to further
enhance IRF7-induced levels of IFN-b, suggesting an additional
level of complexity to the regulation of interferon signalling.
Interestingly, the inhibitory effect of Med23 was specific to HSV-1,
with replication of a range of other viruses including Vaccinia
virus and Semliki Forest Virus being unaffected by Med23
depletion. As Vaccinia virus is resistant to IFN-l anti-viral activity
[62], this observation further highlights the importance of IFN-l,
as opposed to IFN-b, in the anti-viral effect of Med23. The
R617Q mutation in Med23 (R611Q in Med23 transcript variant
Figure 6. Occurrence and severity of clinical HSV-1 reactivation is associated with IFN-l expression. The frequency of genotype of the
single nucleotide polymorphism rs12979860 in the IFN-l3 promoter region in HSV-1 individuals with a range of frequency and severity oral herpes
labialis was determined by PCR. NR, non-recurrent; L, low recurrence; H, high recurrence; H+ high and clinically severe recurrence. Significance of
genotype association was determined by Fisher’s exact test, comparing the frequency of the CC, CT or TT genotype in the NR vs the L, H or H+ clinical
groups. * = p-value 0.014. See also Table 1 and Methods for further details.
doi:10.1371/journal.ppat.1003514.g006
Table 1. Association of the IL28B genetic polymorphism rs12979860 with recurrence and severity of oral HSV-1 labialis.
Genotype
Clinical statusa nb Genderc nb Age range Median age CC CT TT
NR 21 M 5 26–49 39 4 1 0
F 16 27–52 36 10 5 1
L 18 M 6 22–61 43 4 1 1
F 12 23–60 37 8 2 2
H 9 M 2 37–52 44.5 2 0 0
F 7 31–54 42 1 4 2
H+ 9 M 3 35–46 35 1 1 1
F 5 25–55 38 0 3 2
aSN, HSV-1 IgG seronegative; NR, non-recurrent; L, low recurrence; H, high recurrence; H+, high recurrence and clinical severity. See Methods for details.
bn, number of patients.
cM, male; F, female.
doi:10.1371/journal.ppat.1003514.t001
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1, used here) was unable to enhance IRF7-induced IFN-l
expression. This mutation causes hereditary dementia [63], and
the failure to induce IFN-l and thereby control HSV-1 in the
brain may be a potential cofactor for the development of
dementia, similar to Alzheimer’s disease [64].
There is mounting evidence for a role of the IFN-l family in the
regulation of virus pathogenesis [45], particularly in the case of
Hepatitis C infection where a polymorphism in the promoter
region of IFN-l3 (IL-28B; polymorphism rs12979860), which
correlates with plasma levels of IFN-l3 [50], is associated with
disease and treatment outcome [49]. Individuals with recurrent
HSV-1 reactivation have been shown to be deficient in IFN-l
expression [51], and here we found the similar association between
the IFN-l3 promoter polymorphism and ethnically Italian patients
suffering recurrent and severe reactivations of HSV-1-related oral
herpes outbreaks, albeit with a small sample group (n=58).
Furthermore, sporadic mutations and genetic polymorphisms in
innate immune receptor and signalling molecules that lead to the
induction of type I and III IFNs have also been shown to be
associated with Herpes Encephalitis [65], as well as oral and
genital Herpes [66,67].
HSV infection controlled by a complex, interconnected and
highly regulated network of cytokines expressed by innate
immune cells. Type I IFNs mainly produced by HSV-infected
keratinocytes [68] and pDCs [69] inhibit the spread from
neurons to epithelial cells and between epithelial cells [70],
similar to IFN-c. Type III IFNs are also able to directly inhibit
HSV-1 infection in primary neurons, astrocytes, macrophages
and dendritic cells [71,72]. IFN-c levels produced by peripheral
blood CD4+ T-cells correlate with the frequency of HSV-1
reactivation [73]. IFN-l is able to induce expression of both itself
and the type I IFNs, and a similar effect has also been observed
for type I IFNs which induce both type I and III IFNs [71,72].
Type III IFNs are mainly expressed by myeloid dendritic cells
(mDC) and monocyte-derived macrophages [74], and signal
through the heterodimeric IL10RB/IL28RA receptor complex
whose expression is largely restricted to cells of epithelial origin
and plasmacytoid dendritic cells (pDC), in contrast to the broadly
expressed type I IFN receptor (IFN-aR1/2) [75,76]. Since
primary HSV-1 infection and reactivation affects skin and
mucosa in the majority of cases, IFN-l may play a much greater
role in the control of HSV-1 pathogenesis, likely in a complex
network of coregulated type I and II IFNS, than previously
thought. We hypothesize that HSV-infected DCs at the site of the
lesion (such as skin Langerhans DCs whose role in IFN-l
production is currently unknown, or intruding myeloid DCs) in
individuals with the rs12979860 T/T or C/T haplotype express
reduced levels of type III IFNs, and, in consequence, of type I
IFNs, which leads to a reduced inhibition of local HSV-1
replication and the occurrence of fresh skin lesions. However, the
relative contribution of IFN-l1 and l2/3 to the interferon-
mediated control of HSV-1 replication in vivo, and indeed the role
of Med23 in this, remains to be seen.
In summary, this study provides a comprehensive and robust
analysis of HFs that influence HSV-1 replication in vitro, which will
benefit many future studies on HSV-1. The identification of
Med23 as a crucial cellular component for IFN-l expression, and
evidence for the significant role of type III IFN in the innate
immune control of HSV-1 in vitro and in vivo, demonstrates the
power of combined, genome-scale studies to identify physiologi-
cally important HFs for virus pathogenesis. Future studies will
clarify the role of genetic variations in both Med23 and IFN-l in
HSV-1-related diseases, such as meningitis, keratitis and orola-
bial/genital reactivations.
Materials and Methods
siRNA screen
siRNA SMARTpools (4 siRNAs per gene) at 0.3 mM were
dispensed in 10 ml volumes using a Rapidplate384 liquid handler
(Qiagen) into triplicate black 384-well plates (Corning), sealed with
adhesive seals (ThermoFisher) and plastic lids. Plates were stored
at 280uC until needed (minimum 24 h, maximum 48 h). On the
day of transfection, assay plates were thawed at room temperature
and 10 ml transfection reagent (Dharmafect 1, Dharmacon),
diluted in Hank’s buffered saline solution (HBSS, ThermoFisher)
to give a final concentration of 0.1%, was added using a Multidrop
384 (ThermoFisher). Plates were incubated for 20 min at room
temperature to allow formation of transfection complexes. During
complex formation, low-passage (p20–22) Hela cells (ECACC)
from ,50% confluent flasks were washed in PBS and trypsinised
in Trypsin-EDTA (Lonza) before diluting in phenol red-free,
antibiotic-free transfection medium (DMEM/F-12 1:1/5% FCS
with 15 mM Hepes and L-glu; Gibco). Cells were counted and
36103 cells in 40 ml were added to each well using the Multidrop
384. Plates were incubated for 48 h at 37uC in a humidified
incubator with 5% CO2. To infect, media was removed from
plates by inversion, and 10 ml media (as for transfection, but
containing penicillin-streptomycin; Lonza) or virus (HSV-1-eGFP
strain C12, diluted to MOI 0.5 in infection media) [34] was added
using the Multidrop 384. Plates were incubated at 37uC for 1 h
before 50 ml infection media was added and plates returned to the
incubator. Replication was monitored as a function of eGFP
fluorescence from 24 h to 80 h post-infection using the POLAR-
star OPTIMA plate reader (BMG Labtech). Virus replication
slopes over the linear phase were calculated and normalized to
mock transfected wells on individual assay plates, and the mean
replication slope from six replicates used for subsequent data
analyses.
Cell viability assay
Cells were transfected as described above, and the cytotoxicity
of siRNAs was determined using the CellTiter Blue (CTB,
Promega) reagent, which gives a fluorescent or absorbance signal
relative to the number of live cells. Briefly, 5 ml CTB was added
per well using the Multidrop 384. Plates were incubated at 37uC in
a humidified incubator with 5% CO2 for 2 h before measuring
fluorescence (POLARstar OPTIMA plate reader). Readings were
normalized to viability of mock-transfected cells, per plate, and
mean cell viability over three replicates was calculated. Distribu-
tion analysis of cell viability values identified median viability as
60%, and values ,60% were considered cytotoxic.
Yeast two-hybrid protein interaction screen
The HSV-1 clone collection was cloned by recombinatorial
(GATEWAYTM, Invitrogen) and conventional cloning into the bait
vector pGBKT7, and screened against a library pooled from 12,381
MGC clones [35] in the pGADT7 prey vector using a semi-
automated Y2H assay [77]. Interacting prey cDNAs were identified
by sequential blasting of RefSeq, ENSEMBL and Unigene
databases. BLAST hits with identical parameters (score, expectation
value, length of alignment) were considered indistinguishable and
counted separately. A high-confidence dataset was generated from
interaction pairs isolated at least twice, or where the bait interacted
with two highly related, non-promiscuous preys.
Bioinformatic analyses
Interactions between HSV-1 and human proteins were
connected to a network of human protein-protein interactions (a
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total of 62,310) taken from the databases HPRD [78](Release 9),
BioGRID [79], DIP [80], MINT [30] and IntAct (downloaded
May 18th 2010). A high-confidence interaction set (9,829
interactions) was compiled from interactions identified in at least
two studies. Betweenness centrality (g(v) of a protein v was
calculated as g(v)=gs{v{t(sst(v)/sst), where sst is the total number
of shortest paths from protein s to protein t, and sst(v) is the
number of those shortest paths that contain v. Betweenness
centrality was normalized by dividing by the total number of
protein pairs in the network. Enrichment for functional annota-
tions from gene ontology (GO) [81], KEGG [82,83], REAC-
TOME [84,85], and BIOCARTA was performed using DAVID
[86]. Data on known human protein complexes was retrieved from
the CORUM database, and complexes with subunits showing
consistently stronger effects (inhibiting or enhancing) than
expected by chance were detected using Wilcoxon’s rank-sum
test. Genes included in the RNAi screen were ranked by their
distance from the median knockdown, with the most inhibiting
and enhancing genes being ranked highest. FDR was used for
multiple testing correction.
siRNA SMARTpool deconvolution for HSV-1 replication
assay validation
The HSV-1 replication phenotype observed in the primary
screen was validated for a subset of candidates by deconvoluting the
assay SMARTpools. The four individual siRNAs targeting different
regions of each gene, as well as a reconstituted SMARTpool, were
diluted to 0.3 mM in 16 siRNA buffer and dispensed to black 384-
well plates. Transfection and infection was carried out as described
above. Replication slopes were calculated and normalized as
described, and a phenotype was considered validated if two or
more of the four siRNAs resulted in the same, or better, phenotype.
Determination of virus specificity
For inter-viral comparison, siRNAs were considered inhibitory
or enhancing if normalized replication was 626STDEV of the
controls
a) HSV-1 replication assays. Selected siRNA SMARTpools
were diluted to 0.3 mM in 16siRNA buffer and dispensed in black
96-well plates (Corning). To this 10 ml Dharmafect 1, diluted in
HBSS to a final concentration of 0.15%, was added using the
Multidrop 384. Following a 20 min incubation to enable complex
formation, 16104 Hela cells in 80 ml transfection media were
seeded on to the complexes bringing the final volume of
transfection to 100 ml in each well. Plates were incubated for
48 h at 37uC in a humidified incubator with 5% CO2 before
infection. To infect, media was removed from plates by inversion,
and 25 ml media (as for transfection, but containing penicillin-
streptomycin; Lonza) or virus (strain C12, diluted to MOI 0.5 in
infection media) was added using the Multidrop 384. Plates were
incubated at 37uC for 1 h before virus was removed by plate
inversion and 100 ml infection media was added. Plates were
returned to the incubator before replication was monitored as a
function of eGFP fluorescence from 24 h to 80 h post-infection.
Virus replication slopes over the linear phase were calculated and
normalized to mock transfected wells on individual assay plates,
and the mean replication slope from six replicates used for
subsequent data analyses.
b) VZV replication assays. Selected siRNA SMARTpools
were diluted to 0.3 mM in 16siRNA buffer and dispensed in black
384-well plates (Corning). To this, 10 ml Dharmafect 1 diluted in
HBSS to a final concentration of 0.07% was added using the
Multidrop 384. Following a 20 min incubation to enable complex
formation, 2.56103 MeWo cells (ATCC, HTB-65TM) in 40 ml
media (EMEM/10% FCS/1% non-essential amino acids) were
seeded on to the complexes bringing the final volume of
transfection to 60 ml in each well. Plates were incubated for 48 h
at 37uC in a humidified incubator with 5% CO2 before infection.
To infect, media was removed from plates by inversion and ,25
colony forming units of VZV-eGFP-infected MeWo cells (vaccine
strain Oka) [87] diluted in MeWo growth media were seeded on to
the complexes using the Multidrop 384. Virus growth was
measured in 3 h intervals as a function of eGFP fluorescence
from 44 to 72 h post-infection. Virus replication slopes over the
linear phase were calculated and normalized to mock transfected
wells on individual assay plates, and the mean replication slope
from six replicates used for subsequent data analyses.
c) hCMV replication assays. Selected siRNA SMARTpools
were diluted to 0.5 mM in 16siRNA buffer and dispensed in 10 ml
volumes in black 384-well plates (Corning). To this, 10 ml
Dharmafect, 1 diluted in HBSS to a final concentration of
0.2%, was added using the Multidrop 384. Following a 20 min
incubation to enable complex formation, 36103 MRC-5 (ATCC,
CCL-171TM) in 40 ml growth medium (phenol red-free DMEM/
10%FBS/L-glutamine/1% non-essential amino acids were seeded
on to the complexes bringing the final volume of transfection to
60 ml in each well. Plates were incubated for 48 h at 37uC in a
humidified incubator with 5% CO2 before infection. To infect,
media was removed from plates by inversion, and 10 ml media (as
for transfection, but containing penicillin-streptomycin) or virus
hCMV-GFP (strain AD169) [88], diluted to MOI 0.5 in infection
media, was added using the Multidrop 384. Plates were incubated
at 37uC for 1 h before 50 ml infection media was added and plates
returned to the incubator prior to monitoring virus replication.
Replication was monitored as a function of eGFP fluorescence
from 24 h to 80 h post-infection using the POLARstar OPTIMA
plate reader (BMG Labtech). Virus replication slopes over the
linear phase were calculated and normalized to mock transfected
wells on individual assay plates, and the mean replication slope
from six replicates used for subsequent data analyses.
d) SFV replication assays. Selected siRNA SMARTpools
were diluted to 0.5 mM in 16siRNA buffer and dispensed in 10 ml
volumes in black 96-well plates (Corning). To this, 10 ml
Dharmafect 1 diluted in HBSS to a final concentration of
0.15% was manually added. Following a 20 min incubation to
enable complex formation, 46104 Hela cells in 80 ml transfection
media (DMEM/5% FCS/L-glu) were seeded on to the complexes
bringing the final volume of transfection to 100 ml in each well.
Plates were incubated for 48 h at 37uC in a humidified incubator
with 5% CO2 before infection. To infect, media was removed
from plates by inversion, and 25 ml media (as for transfection, but
containing penicillin-streptomycin; Lonza) or virus (SFV4(3H)-
Rluc [89] diluted in phosphate buffered saline (PBS)/0.75%
bovine serum albumin to an MOI 0.01) was manually added.
Plates were incubated at 37uC for 1 h before media (as for
transfection media) was added manually to increase the volume to
100 ml per well. Plates were incubated at 37uC for 24 h before cells
were lysed using a passive lysis buffer and Renilla luciferase levels
measured with a microplate reader (Promega) using a dual
luciferase reporter assay kit (Promega). Luciferase activity, which is
representative of virus genome replication, was normalized to
mock-transfected cells and mean luciferase activity from six
replicates used for subsequent data analyses.
e) Vaccinia virus replication assays. Hela cells were
transfected as described in primary siRNA screen. Plates were
incubated for 48 h at 37uC in a humidified incubator with 5%
CO2 before infection. To infect, media was removed from plates
by inversion, and 15 ml media (as for transfection, but containing
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penicillin-streptomycin) or 15 ml media containing Vaccinia virus
strain WR with eGFP-tagged A5 protein [90], diluted to MOI
0.05, was added using the Multidrop 384. Plates were incubated at
37uC for 1 h before 50 ml of media was added to each well, the
plates inverted to remove the media and virus, and a final volume
of 50 ml of media added to the plates before they were returned to
the incubator. Replication was calculated as a function of eGFP
fluorescence at 48 h post-infection using the POLARstar OPTI-
MA plate reader (BMG Labtech). Virus replication was normal-
ized to mock transfected wells on individual assay plates, and the
mean replication from eight replicates used for subsequent data
analyses.
qPCR for siRNA knockdown
Hela cells were transfected with selected SMARTpool siRNAs
in 96-well plates, in triplicate, as described. After 48 h transfection,
medium was removed, cells rinsed in PBS and lysed in 100 ml
TRIZOL (Invitrogen). Triplicate wells were combined, and RNA
extracted by standard phenol:chloroform extraction methods. mRNA
levels were determined by TaqMan qPCR, using the one-step RT-
qPCR kit (Thermofisher), with gene-specific primers (Table S9 in
Text S2), and probes from the Universal Probe Library (Roche).
Expression levels normalized to the housekeeping cellular gene
hypoxanthine phosphoribosyltransferase 1 (HPRT) and calibrated to
mock-transfected cells. qPCR was carried out in duplicate for each
sample, and the mean of normalized expression levels calculated.
LUMIER pull-down assay for validating Y2H protein
interactions
Proteins were transiently expressed in HEK293 cells as hybrid
proteins with the Staphylococcus aureus protein A tag or Renilla reniformis
luciferase fused to their amino termini. 20 ng of each expression
construct were transfected into 16104 HEK293 cells using 0.05 ml
of lipofectamine 2000 (Invitrogen) in 96-well plates. After 40 h,
medium was removed and cells were lysed on ice in 10 ml of ice-cold
lysis buffer (20 mM Tris pH 7.5, 250 mM NaCl, 1% TritonX-100,
10 mM EDTA, 10 mMDTT, Protease Inhibitor Cocktail (Roche),
Phosphatase Inhibitor Cocktail (Roche), Benzonase (Novagen) 25
units per ml final concentration) containing sheep-anti-rabbit IgG-
coated magnetic beads (Invitrogen, Dynabeads M280, 2 mg/ml
final concentration). Lysates were incubated on ice for 15 minutes.
100 ml of wash buffer (PBS, 1 mM DTT) were added per well, and
10% of the diluted lysate was removed to determine the luciferase
activity present in each sample before washing. The remaining
sample was washed 6 times in wash buffer in a Tecan Hydroflex
plate washer. Luciferase activity was measured in the lysate as well
as in washed beads. Negative controls were wells transfected with
the plasmid expressing the luciferase fusion protein and a vector
expressing two copies of protein A. For each sample, four values
were measured: the luciferase present in 10% of the sample before
washing (‘‘input’’), the luciferase activity present on the beads after
washing (‘‘bound’’), and the same values for the negative controls
(‘‘input nc’’, and ‘‘bound nc’’). Normalized interaction signals were
calculated as follows: Log(bound)/log(input) – log(bound nc)/
log(input nc). Normalized interaction signals were z-transformed
by subtracting the mean and dividing by the standard deviation.
The mean and standard deviation were calculated from large
datasets of protein pairs which were not expected to interact, i.e.
from negative reference sets.
HSV-1 microscopy
Selected siRNAs SMARTpools were diluted to 500 nM in
HBSS and 40 ml was incubated with 40 ml Dharmafect 1 diluted in
HBSS to a final concentration of 0.15%. After 20 min incubation,
36104 Hela cells in 320 ml transfection medium were added,
mixed with the transfection complexes and transferred to 8-well
glass bottomed chamber slides (Becton Dickinson). Plates were
incubated for 48 h at 37uC in a humidified incubator with 5%
CO2 before infection by removing medium and adding 100 ml
HSV-1-eGFP at a MOI of 1. After incubation for 1 h at 37uC,
virus was removed and replaced with 500 ml growth medium.
Images were acquired 48 h post-infection.
Flow cytometry of HSV-1-eGFP infected cells
Select siRNAs SMARTpools were diluted to 500 nM in HBSS
and 100 ml was incubated with 100 ml Dharmafect 1 diluted in
HBSS to a final concentration of 0.15% in individual wells of a 12-
well plate. After 20 min incubation, 26105 Hela cells in 800 ml
transfection medium were added. Plates were incubated for 48 h at
37uC in a humidified incubator with 5% CO2 before infection by
removing medium and adding 500 ml HSV-1-eGFP at a MOI of 1.
After incubation for 1 h at 37uC, virus was removed and replaced
with 2 ml growth medium. After 48 h, medium was removed, cells
rinsed in PBS and dislodged by trypsinisation. Cells were washed in
PBS and pelleted by centrifugation for 10 min at 199 g. Superna-
tant was removed and cells fixed in 4% paraformaldehyde before
analysing for eGFP expression by flow cytometry (FACS DiVa, BD
Biosciences) using the CellQuest software package.
Transient and stable over-expression of Med23
For transient over-expression, 1.56104 HEK293 cells were
seeded in black 96-well plates. The following day, cells were
transfected with 100 ng pCR3-Med23 using LipofectamineTM
LTX (Invitrogen) and incubated for 48 h before infection with the
recombinant HSV-1 reporter viruses C12 and VP26-YFP at MOI
0.5. Replication growth curves were monitored, and endpoint
replication (as determined by fluorescence) was normalized to
untransfected cells. For stable expression, Hela cells were
transduced with pLenti-Med23, generated using the ViraPowerTM
Lentiviral Expression System (Invitrogen), as per manufacturers’
instructions. Stable cells were infected, and replication monitored,
as above. For confirmation of overexpression, RNA was extracted
(QIAGEN RNA-easy kit) and expression quantified by one-step
RT-qPCR (Thermofisher), with gene-specific primers (Table S9 in
Text S2), and probes from the Universal Probe Library (Roche).
Expression levels were normalized to the housekeeping cellular
gene hypoxanthine phosphoribosyltransferase 1 (HPRT) and
calibrated to mock-transfected cells. qPCR was carried out in
duplicate for each sample, and normalized expression levels
averaged. The VP26-YFP reporter virus was generated from a
KOS BAC kindly provided by David Leib using the Red-mediated
recombination system, where the first 4 amino acids of VP26 were
replaced with YFP [91,92,93].
Effect of Med23 in Stat1-deficient A549-V cells
The effect of Med23 over-expression and depletion was
investigated in interferon-deficient cells. The human alveolar
epithelial cell line A549, and A549-V, a Stat1-deficient derivative
cell line stably expressing the V protein from Simian virus 5 [43],
were seeded at 26104 cells per well in a 96-well plate, and
transfected with Med23 siRNA or pCR3-Med23 and infected as
described for Hela cells.
qRT-PCR analysis of interferon and cytokine induction
A549 cells were transfected with 100 ng pCR3 or Med23
overexpression plasmids, or RSCF or Med23 SMARTpool siRNA
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(50 nM) in duplicates, in 96-well plates as described. RNA was
harvested 20 h post-transfection, and mRNA expression levels
quantified by qRT-PCR, as described.
IFN-l ELISA
Induction of IFN-l by Med23 was determined in a range of cell
types by seeding cells in 96-well plates to be ,80% confluent the
next day. Cells were transfected in duplicates with 100 ng pCR3
or pCR3-Med23 using Lipofectamine LTX with Plus reagent
(Invitrogen), in antibiotic-free medium. IFN-l levels quantified
96–120 h post-transfection. The synergistic effect of Med23 and
IRFs on IFN-l induction was determined by co-transfection of
pCR3 or pCR3-Med23 (50 ng) with pCR3-IRF7 (50 ng) in A549
cells, with Lipofectamine LTX with Plus reagent. The effect of
Med23 depletion on IFN-l induction was determined by
transfection of A549 cells in 96-well plates with 50 nM RSCF or
Med23 siRNA. IFN-l was quantified 120 h post-transfection.
IFN-l protein expression was quantified in supernatants using a
commercial IFN-l DuoSet ELISA kit (R and D Systems).
IFN-l1 luciferase reporter assay
A point mutation (R611Q) was introduced into Med23
(Transcript Variant 1) by PCR with specific primers (see Table
S9 in Text S2) and the clone verified by sequence analysis. A549
cells were co-transfected with 60 ng of pCR3, pCR3-Med23 or
pCR3-R611Q, 60 ng of pCR3-IRF7, 20 ng of IFN-b-, IFN-l1- or
ISRE-responsive luciferase reporter constructs and 10 ng pRL-
TK, a Renilla Luciferase transfection control, in antibiotic-free
low serum (1%) medium. After 33 h cells were lysed, and firefly
(promoter reporter construct) and Renilla (transfection control)
luciferase activity was measured (Dual-Luciferase Reporter Kit,
Promega). Relative luminescence activity was normalized to
Renilla (as a transfection control).
Interferon stimulation assays
A549 cells were transfected in triplicate in black 96-well plates,
as described. After incubation at 37uC for 24 h, cells were serum-
starved for 24 h by growing in low serum (1%) medium, before
cells were left untreated or stimulated with 50 ng/ml IFN-a, IFN-
b or IFN-c, or 100 ng/ml IFN-l1 or IFN-l2/3 in serum-reduced
medium. After 6 h cells were infected with HSV-1 C12 diluted to
MOI 0.5 in IFN-containing serum-reduced medium. After 1 h
incubation, virus was removed and media replaced with 100 ml
serum-reduced growth medium containing no interferon, IFN-a/-
b/-c at 50 ng/ml, or IFN-l1/-l2/3 at 100 ng/ml. Replication
was monitored as described and normalized to replication in
mock-transfected, unstimulated cells.
Med23 interaction with IRF7
Potential interactions between Med23 and the IRFs were
determined by yeast two-hybrid analysis and confirmed by co-
immunoprecipitation (Co-IP) in mammalian cells.
a) Co-immunoprecipitation. Co-immunoprecipitation was
performed using the epitope-tagged plasmids pGBKT7 (Myc
epitope) and pGADT7 (HA epitope) containing the T7 promoter,
and recombinant vaccinia virus vTF-7 expressing the T7 RNA
polymerase (NIH AIDS repository). 56106 HEK293 cells were
seeded in 10 cm dishes and the following day infected with vTF-7
(MOI 10) for 1 h before transfecting 10 mg each of empty bait
(pGBKT7) or Med23-Bait, and IRF-Prey (pGADT7) vectors with
Lipofectamine (Invitrogen). After 48 h cells were lysed on ice for
30 min in NP40 buffer, containing protease and phosphatase
inhibitors. Debris was removed by centrifugation, and protein
quantified with a BCA protein assay kit (Thermo scientific, UK) as
per manufacturers’ instructions. Equal protein quantities (650 mg
per sample) were pre-cleared by continuous mixing with 50 ml pre-
equilibrated Protein G Sepharose beads for 1 h at 4uC. Samples
were centrifuged and supernatants halved before overnight mixing
incubation with beads pre-coated with 1 mg a-HA (Roche, UK) or
a-c-Myc (Santa Cruz, UK) at 4uC. Beads with precipitated
proteins were washed three times with ice-cold NP40 buffer,
resuspended in 26 SDS protein sample buffer and boiled for
10 min before SDS-PAGE separation on two 8% polyacrylamide
gels. Proteins were transferred onto nitrocellulose membranes
overnight at 4uC before blocking with 5% milk in TBS-Tween
then incubating with either a-HA or a-myc antibody (diluted
1:1000 in 5% milk/TBS-Tween). Membranes were washed in
TBS-Tween before incubation with HRP-conjugated secondary
antibody (diluted 1:3000 in 5% milk/TBS-Tween). After further
washes, proteins were detected by incubation with ECL Western
blotting detection system, exposing to X-ray film and developing
films in an OPTIMAX X-Ray film processor.
b) Yeast two-hybrid assays. Haploid yeast strains AH109
and Y187 were transformed with 1 mg prey (pGADT7 or
pGADT7-IRF1, -IRF2, -IRF3, -IRF4, -IRF5, -IRF7 or -IRF9)
or bait (pGBKT7 or pGBKT7-Med23) plasmid DNA, respective-
ly, and grown overnight in synthetic defined (SD) medium lacking
either leucine (-L; Prey) or tryptophan (-W; Bait) before prey- and
bait-expressing haploid yeast cells were mated overnight in SD-
LW/5% YPDA medium. Haploids were selected in SD-LW for
48 h before transferring to triple-knockout, histidine-deficient SD-
LWH liquid medium containing 3-aminotriazol (3-AT) and 4-
methylumbelliferyl-b-D-galactopyranoside (4-MuX) for 5–7 days.
Interactions were tested in quadruplicates, detected by growth of
colonies on SD-LWH agar with 3-AT, and quantified by
measurement of fluorescence released from a-galactosidase
cleavage of 4-MuX upon protein interaction. Relative fluorescence
(RFU) was normalized to negative control interaction (empty
pGADT7 mated with empty pGBKT7).
Genotypic analysis of the IFN-l3 promoter
Ethnically Italian subjects with or without a history of recurrent
Herpes labialis (HL) gave written voluntary informed consent and
were enrolled in this study at the University of Rome Tor Vergata
with the approval of the Ethical Committee at the University of
Rome Tor Vergata. All subjects were interviewed by medically
trained investigators using an appropriate questionnaire and
agreed to provide saliva and/or blood samples. Data and blood
sample collection was carried out as previously described [51]. A
total of 58 healthy immunocompetent individuals (17 men and 41
women) age 22–61 years (overall median age 38.5 yr; male
median age 40 yr, range 22–61; female median age 38, range 23–
60) participated in the study. None of the patients presented with
an active lesion at the time of or in the 3 weeks preceding saliva
sample collection. For the purpose of this study, patients were
characterized into no recurrence of HL (NR), low recurrence (L;
1–3 HL episodes/yr, with a maximum extension of 1 cm, mild
symptoms and healing time ,7 days), high recurrence (H; 4 or
more HL episodes/yr, extension of lesions more than 1 cm), very
high recurrence (H+; more than 4 HL episodes/yr, extension of
lesions .3 cm and/or involving nose or cheek beyond the lip,
more severe and long lasting associated symptoms including itch,
burning, paresthesias and/or neuralgia, with healing times .7
days and who required antiviral therapy). The NR group consisted
of 21 individuals (16 women [median age (range) 36 (27–520] and
5 men [median age (range) 39 (26–49)]. The L consisted of 18
Med23-IFN-l Regulation of HSV-1 Replication
PLOS Pathogens | www.plospathogens.org 15 August 2013 | Volume 9 | Issue 8 | e1003514
individuals (12 women [median age (range) 37 years (23–60)] and
6 men [median age (range) 43 years (22–61)]). The H group
consisted of 9 individuals (7 women [median age (range) 42 years
(31–54)] and 2 men [median age (range) 44.5 years (37–52)]). The
H+ group consisted of 8 individuals (5 women [median age (range)
38 years (28–55)] and 3 men [median age (range) 35 years (35–
46)]). Saliva samples (,3 ml) were obtained from each subject
after an overnight fast and after rinsing the mouth twice with
water, split into two aliquots and frozen at 220uC. Samples were
anonymised and stored with dual code labels before shipping on
dry ice to the University of Edinburgh for DNA extraction. Saliva
and PBMC samples were thawed and DNA extracted using a
QIAamp DNA Blood Mini Kit (Qiagen) as per manufacturer’s
instructions, quantified using a NanoDrop and IL28B genotype
determined by melt-curve analysis PCR on a LightCycler480
(Roche) using the LightMixH Kit IL28B (TIB Molbiol) as per
manufacturer’s instructions. Significance of genotype association
was determined by Fisher’s exact test, comparing the frequency of
the CC, CT or TT genotype in the NR group versus the L (p-
value = 1), H (p-value = 0.12) or H+ (p-value = 0.015) clinical
groups.
Below lists the GeneID numbers for genes and proteins
mentioned within the text of this manuscript: IFITM1 (8519);
IFN-a (cluster; 3438); IFN-b (3456); IFN-c (3458); IFN-l1
(282618); IFN-l2 (282616); IFN-l3(282617); IL10RB (3588);
IL28RA (163702); IRF4 (3662); IRF7 (3665); IRF9 (10379);
MED4 (29079); MED6 (10001); MED7 (9443); MED8 (112950);
MED14 (9282); MED16 (10025); MED17 (9440); MED21 (9412);
MED23 (9439); MED25 (81857); MED26 (9441); MED27 (9442);
MED28 (80306); MED29 (55588); NR3C2 (4306).
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appropriate references.
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Text S2 Supporting tables. Table S1 – 358 Top 2.5%
inhibitory and enhancing genes. Table S2 – Overlap of primary
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– Specificity of identified HFs to HSV-1 replication. Table S8 –
Functional and pathway analysis of siRNA HFs. Table S9 –
Primers and probes for qPCR assays.
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Figure S1 Pathogen-host interactome analysis of RNAi
and Y2H HFs. (a) Combined HSV-1-human interactomes with
intraviral, virus-host and high-confidence host-host interactions.
Green, viral proteins; Pink, direct (level 1) interactors (Y2H
screen); Blue, level 1 interactors (Y2H/RNAi screens); Cyan, host
protein-protein (level 2) interactors (Y2H screen); Yellow, Level 2
interactors (Y2H/RNAi screens). Due to the large size of the
human network, and in order to discern viral proteins, only the
first two levels were plotted (inset: all levels). Combined HSV-1-
human interactome. Inset, all levels. (b) Intraviral and virus-host
degree (# interactions) distribution of HSV-1 proteins. (c)
Correlation between intraviral and virus-host degrees in HSV-1.
(d) Degree comparison of cellular interactors versus all proteins in
human networks, where the degree indicates the number of
interactions a particular protein has. (e) Betweenness centrality
comparison of cellular interactors versus all proteins in human
networks, where betweenness indicates the number of shortest
paths between a protein pair, passing through the protein of
interest. Statistically significant differences between viral targets
and remaining proteins are denoted by *. (f) Distribution of HFs in
the virus-host interactomes. Level 1 proteins are direct interactors
with HSV-1 proteins, level 2 their interactors and so on. (g)
Validation of HSV-1-host Y2H interactors. A subset of protein
interactions identified in the HSV-1-host Y2H screen were
validated using the LUMIER pull-down assay in a mammalian
cell system. Strength of interaction was determined by Z-score,
where a score 1 to 2 represents a weak interaction and score .2
represents a strong interaction. (h) Distribution of direct HSV-1
targets in the RNAi screen. The proteins directly targeted by
HSV-1 were taken from the Y2H data set and from the literature
curation. An enrichment of literature-derived targets could be
observed in the top 5% most inhibiting knockdowns (2.4-fold
enrichment; p=0.008), but the same could not be observed for the
Y2H-detected direct targets.
(TIF)
Figure S2 Validation of HF identified by RNAi. HFs
identified in the HSV-1 perturbation screen were validated with
deconvoluted siRNAs and qPCR: (a) chromoboxes, (b) homeo-
boxes, (c) general transcription factors, (d) nuclear receptors, (e)
proteasome family members, (f) topoisomerases, (g) mediator
complex subunits, (h) proteins involved in vesicle transport, (i)
integrins, (j) Y2H interactors, (k) ubiquitin E2 ligases, (l) vesicle
transport – further candidates, (m) interferon-stimulated mem-
brane proteins and (n) others. HSV replication is presented as
normalized replication slope, and is the mean of six individual
assay points. Error bars represent standard deviation of the six
data points. Deconvoluted siRNAs which had a sequence different
to that in the original screen are highlighted in red. Genes for
which the primary screen phenotype was not confirmed in the
deconvolution assay are shown in bold text.
(TIF)
Figure S3 HSV-1 HFs are involved in diverse cellular
pathways and at multiple stages of the HSV life cycle.
Enrichment of protein functions among the HSV-1 HFs. The
enrichment for gene ontology (GO) terms and KEGG, BIO-
CARTA or REACTOME pathway annotations among the HSV-
1 HFs identified by (a) RNAi and (b) Y2H assay was performed
using DAVID bioinformatics software. (c) Direct interactions
between human and HSV-1 proteins. The protein-protein
interactions (PPIs) depicted are from the high confidence Y2H
data set and from literature curation. Circles and diamonds
correspond to human and HSV-1 proteins, respectively. Human
proteins detected in the Y2H screen are drawn with red borders.
Human genes that showed the strongest effects in the RNAi screen
are colored yellow (extreme 10%) and orange (extreme 5%). (d)
Highly interconnected regions in the human interaction network
composed of HFs. Highly interconnected regions in the human
interaction network composed of HFs. We assembled a human
interaction network using data from the major PPI databases. A
subnetwork consisting of HFs was then defined by limiting the
network to the HFs detected in the Y2H screen, the RNAi
(extreme 5%) screen, and the literature curation. Highly
interconnected regions in the subnetwork were sought out using
the MCODE algorithm. The top six scoring regions are shown.
Proteins displayed in red correspond to HFs that are known only
from the literature, and those in green are those that were detected
in either of the screens performed in this study. The three boolean
values beside each gene symbol represent whether the HF is
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present in the Y2H screen, the RNAi screen (extreme 5%), or the
literature curated set, in that order. Dominant functional
categories could be observed in each of the regions, including
transcription (e.g., Mediator complex, RNA polymerase II and
associated genes), translation initiation, splicing, and intracellular
transport.
(TIF)
Figure S4 HFs involved in viral entry and capsid
transport. (a) Diagrammatic summary of the role of dynein
chains in HSV-1 infection. (b) Microtubule transport is required
for HSV-1 infection. The role of dynein microtubule transport
components in HSV-1 replication was analysed by comparing the
replication slope of HSV-1-eGFP (C12)-infected cells depleted for
a range of dynein chains from the primary siRNA perturbation
screen. Error bars represent the mean of three independent
experiments done in duplicate. (c) Depletion of dyneins inhibits
virus particle release. The effect of dynein chain depletion on
HSV-1 particle release was determined by quantifying virus titer in
supernatants of Hela cells depleted of DYNC1H1 (heavy chain),
DYNC1I2 (intermediate chain) and DYNC2LI1 (light intermedi-
ate chains) in a high multiplicity (MOI 5; HSV-1 KOS) growth
assay. Titers were compared to control transfected cells (NT, non-
targeting siRNA). (d) Depletion of dynein chains prevents
immediate-early gene expression. Immediate-early (ICP0) and
late (VP16) viral protein expression in cells depleted of
DYNC1H1, DYNC1I2 or DYNC2LI1 was analysed and
quantified by Western blot. Levels were compared to control
transfected cells (NT, non-targeting siRNA). (e) Quantification of
ICP0 and VP16 protein expression. Protein levels of ICP0 and
VP16 in cells depleted of DYNC1H1, DYNC1I2 or DYNC2LI1
were quantified with an Odyssey Imager and normalized to
protein levels in control transfected cells (Non-targeting siRNA).
(TIF)
Figure S5 E2 ubiquitin conjugating enzymes in HSV-1
immune evasion. (a) Depletion of E2 ubiquitin ligases inhibits
PML degradation following HSV-1 infection. Hela cells mounted
on coverslips were depleted for a range of E2 ubiquitin ligases for
24 h before infecting with HSV-1 17+. Cells were fixed and
stained for ICP0 (green) and PML (red), analysed by confocal
microscopy and PML-positive cells were counted (5 fields of view
per coverslip) and expressed as a mean percentage of PML-
positive cells remaining (3 independent experiments). Error bars
represent the standard deviation over 3 independent experiments.
(b) Inhibition of PML degradation by E2s is ICP0-dependent.
Hela cells were seeded on coverslips, transfected as above and
infected with an ICP0 RING-finger deletion mutant (FXE).
Remaining PML-positive cells were quantified as above. (c)
Immunofluorescence staining for PML bodies in cells transfected
with control siRNA not incorporated into the RISC complex
(RSCF) or cells depleted of the E2 ubiquitin conjugating enzymes
E2D1 or E2L3. The arrows highlight cells that have wt PML levels
remaining in them whilst containing wt ICP0.
(TIF)
Figure S6 Med23 is an anti-viral component of the
largely pro-viral multi-protein Mediator complex. (a)
Diagrammatic summary of the role of Mediator complex subunits
in virus replication. Subunits are coloured according to whether
HSV-1 replication was unchanged (grey), inhibited (top 5%, red;
top 10%, orange) or enhanced upon gene knockdown (top 5%,
light green; top 10%, dark green). Subunits not included are white;
herpesvirus proteins reported to target Mediator subunits are
violet; Mediator subunits detected in other viral RNAi screens are
highlighted by coloured diamonds. (b) Mediator complex subunits
influence HSV-1 replication. Individual subunits of the Mediator
complex and associated proteins were depleted by siRNA
knockdown and infected with HSV-1 C12 (MOI 0.5). Replication
was monitored over multiple rounds and the slope of replication
over the linear phase was calculated and normalized to controls
(mock-transfected cells). Grey, no significant effect; red, strongly
pro-viral; green, strongly anti-viral. Error bars represent the mean
of six replicates. (c) Stable or transient overexpression of Med23.
Med23 was stably (HEK) or transiently (Hela) overexpressed and
Med23 mRNA levels quantified by RT-PCR. Expression was
normalized to HPRT and calibrated to parental cells. Error bars
represent the standard deviation of technical replicates.
(TIF)
Figure S7 Med23 inhibits HSV-1 by directly interacting
with IRF7 to induce a Type III, IFN-l interferon
response. (a) Med23 specifically induces interferons. A549 cells
were transfected with pCR3 or Med23 and induction of a panel of
cytokines and interferons determined by qRT-PCR. Expression
was normalized to HPRT and calibrated to pCR3-transfected
cells. Error bars represent the standard deviation of technical
replicates. (b) Med23 directly interacts with IRF7. Haploid yeast
expressing Med23-bait or IRF-prey constructs were mated in
nutrition-deficient Media containing 4-MuX. Interactions were
detected by measurement of fluorescence released by a-galacto-
sidase cleavage of 4-MuX upon protein interaction. Relative
fluorescence (RFU) was normalized to the negative control (2,
empty bait mated with empty prey constructs). Error bars
represent the standard deviation of technical quadruplicates. +,
known interactors Myc and Max. (c) Med23 and IRF7
synergistically induce IFN-l secretion. A549 cells were transfected
with pCR3, Med23, IRF7 or Med23 with IRF7 and supernatant
was harvested after 96 h to measure IFN-l3 levels (pg/ml) by
ELISA. Error bars represent the standard deviation of biological
replicates, and the chart is representative of multiple experiments.
(d) Quantification of Med23 and IRF7 following overexpression.
A549 cells were transfected with pCR3, Med23, IRF7 or Med23
with IRF7 and mRNA expression levels of Med23 or IRF7
quantified by qRT-PCR 96 h post-transfection. Error bars
represent the standard deviation of biological replicates, and the
chart is representative of multiple experiments.
(TIF)
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